HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thulesen, J Articles by Poulsen, S S Search for Related Content PubMed PubMed Citation Articles by Thulesen, J Articles by Poulsen, S S Topic Collections Relevant Article

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice

¹ Department of Medical Anatomy, Section B, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
² Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Correspondence to:
Correspondence to:
Dr J Thulesen
Naestved Hospital, Department 18, Ringstedgade 61, 4700 Naestved, Denmark; J.Thulesen{at}dadlnet.dk

ABSTRACT
Background: Glucagon-like peptide 2 (GLP-2) is an intestinotrophic mediator with therapeutic potential in conditions with compromised intestinal capacity. However, growth stimulation of the intestinal system may accelerate the growth of existing neoplasms in the intestine.

Aims: In the present study, the effects of GLP-2 treatment on the growth of chemically induced colonic neoplasms were investigated.

Methods: In 210 female C57bl mice, colonic tumours were initially induced with the methylating carcinogen 1,2-dimethylhydrazine (DMH) and mice were then treated with GLP-2. Two months after discontinuation of the carcinogen treatment, 135 of the mice were allocated to one of six groups which were treated twice daily with 25 µg GLP-2, 25 µg Gly2-GLP-2 (stable analogue), or phosphate buffered saline for a short (10 days) or long (one month) period. The remaining 75 mice had a treatment free period of three months and were then allocated to groups subjected to long term treatment, as above.

Results: Colonic polyps developed in 100% of the mice, regardless of treatment. Survival data revealed no statistical significant differences among the different groups but histopathological analysis demonstrated a clear and significant increase in tumour load of mice treated with Gly2-GLP-2. The tumour promoting effect of native GLP-2 was less pronounced but the number of small sized polyps increased following long term treatment.

Conclusions: The present results clearly indicate that GLP-2 promotes the growth of mucosal neoplasms. Our findings highlight the need for future investigations on the effects of GLP-2 in conditions needing long time treatment or with increased gastrointestinal cancer susceptibility.

Abbreviations: GLP-2, glucagon-like peptide 2; DMH, 1,2-dimethylhydrazine; PBS, phosphate buffered saline

Keywords: intestinal carcinogenesis; 1,2-dimethylhydrazine; glucagon-like peptide 2; mice

Relevant Article

Effects of growth factors and receptor blockade on gastrointestinal cancer

R J Playford, H Wassan, and S Ghosh
Gut 2004 53: 1059-1063. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				J. A. Koehler, W. Harper, M. Barnard, B. Yusta, and D. J. Drucker Glucagon-like Peptide-2 Does Not Modify the Growth or Survival of Murine or Human Intestinal Tumor Cells Cancer Res., October 1, 2008; 68(19): 7897 - 7904. [Abstract] [Full Text] [PDF]

				P. E. Dube, K. J. Rowland, and P. L. Brubaker Glucagon-Like Peptide-2 Activates -Catenin Signaling in the Mouse Intestinal Crypt: Role of Insulin-Like Growth Factor-I Endocrinology, January 1, 2008; 149(1): 291 - 301. [Abstract] [Full Text] [PDF]

				K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib Clin. Cancer Res., September 1, 2007; 13(17): 5170 - 5175. [Abstract] [Full Text] [PDF]

				P. E. Dube and P. L. Brubaker Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E460 - E465. [Abstract] [Full Text] [PDF]

				D. L. Sigalet, L. E. Wallace, J. J. Holst, G. R. Martin, T. Kaji, H. Tanaka, and K. A. Sharkey Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2 Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G211 - G221. [Abstract] [Full Text] [PDF]

				P. A. Kitchen, R. A. Goodlad, A. J. FitzGerald, N. Mandir, M. A. Ghatei, S. R. Bloom, J. Berlanga-Acosta, R. J. Playford, A. Forbes, and J. R.F. Walters Intestinal Growth in Parenterally-Fed Rats Induced by the Combined Effects of Glucagon-like Peptide 2 and Epidermal Growth Factor JPEN J Parenter Enteral Nutr, July 1, 2005; 29(4): 248 - 254. [Abstract] [Full Text] [PDF]

				R J Playford, H Wassan, and S Ghosh Effects of growth factors and receptor blockade on gastrointestinal cancer Gut, August 1, 2004; 53(8): 1059 - 1063. [Abstract] [Full Text] [PDF]